For the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation with one or more risk factors, dabigatran has an added therapeutic value in comparison with vitamin K antagonists.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.